Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut experience

Weber, Damien Charles; Rutz, Hans; Pedroni, E.; Bolsi, Alessandra; Timmermann, Beate; Verwey, Jorn; Lomax, Anthony; Goitein, Gudrun

doi:10.1016/j.ijrobp.2005.02.023

Cited by 186 publications

(90 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IMPT is routinely delivered to cancer patients at PSI (Switzerland) (14,16,18). The work on development and clinical implementation of IMPT is currently under way at MGH and other proton centers in the US and internationally.…”

Section: Discussionmentioning

confidence: 99%

“…The experience with IMPT at Paul Scherrer Institut (Switzerland) demonstrated a potential for improved tissue sparing in a number of sites, including intracranial, nasopharyngeal and paraspinal lesions (14)(15)(16)(17)(18). While intensity-modulation has been identified as a means to achieve prostate dose escalation (12), IMPT treatment of prostate cancer has not yet been performed anywhere.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiotherapy Treatment of Early-Stage Prostate Cancer with IMRT and Protons: A Treatment Planning Comparison

Trofimov

Nguyen

Coen

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

197

163

View full text Add to dashboard Cite

Purpose-To compare intensity-modulated photon radiotherapy (IMRT) with 3D-conformal proton therapy (3D-CPT) for early stage prostate cancer, and explore the potential utility of intensitymodulated proton therapy (IMPT).Methods-Ten patients were planned with both 3D-CPT (2 parallel-opposed lateral fields) and IMRT (7 equally spaced coplanar fields). Prescribed dose was 79.2 Gy (or cobalt Gray-equivalent, CGE for protons) to the prostate gland. Dose-volume histograms, dose conformity, and equivalent uniform dose (EUD) were compared. Additionally, plans were optimized for 3D-CPT with nonstandard beam configuration, and for IMPT assuming delivery with beam scanning.Results-At least 98% of the PTV received the prescription dose. IMRT plans yielded better dose conformity to the target, while proton plans achieved higher dose homogeneity, and better sparing of rectum and bladder in the range below 30 Gy/CGE. Bladder volumes receiving over 70 Gy/CGE (V 70 ) were reduced, on average, by 34% with IMRT vs. 3D-CPT, while rectal V 70 were equivalent. EUD from 3D-CPT and IMRT plans were indistinguishable within uncertainties, for both bladder and rectum. With the use of small-angle lateral-oblique fields in 3D-CPT and IMPT, the rectal V 70 was reduced by up to 35% compared to the standard lateral configuration, while the bladder V 70 increased by less than 10%.Conclusions-In the range over 60 Gy/CGE, IMRT achieved significantly better sparing of the bladder, while rectal sparing was similar with 3D-CPT and IMRT. Dose to healthy tissues in the range below 50% of the target prescription was substantially lower with proton therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Radiotherapy Treatment of Early-Stage Prostate Cancer with IMRT and Protons: A Treatment Planning Comparison

Trofimov

Nguyen

Coen

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

197

163

View full text Add to dashboard Cite

show abstract

“…[15][16][17][18][19] Various prognostic factors, including but not limited to sex, [20][21][22][23] age, 15,16 and tumor volume, 16,22,[24][25][26] have been identified for this neoplasm, but the clinical significance remains questionable, because these findings are not consistent. For instance, female sex has been suggested as a negative prognostic feature in some but not all studies.…”

Section: Introductionmentioning

confidence: 99%

Incidence and relative survival of chordomas

Smoll

Gautschi

Radovanović

et al. 2013

Cancer

Self Cite

167

View full text Add to dashboard Cite

BACKGROUND: Chordomas are rare bone tumors arising from remnants of the embryonic notochord. METHODS: Data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to calculate the incidence, relative survival (RS), and standardized mortality ratio (SMR) of patients diagnosed with intracranial and extracranial chordomas and to assess the effects of age and sex on this disease. RESULTS: The overall incidence of extracranial and intracranial chordomas was 8.4 per 10 million population. The median overall survival of patients with chordoma patients was 7.7 years. The median survival was 7.7 years for male patients and 7.8 years for female patients. Younger patients (aged <40 years) survived longer compared with older patients (10-year RS, 68% vs 43%). The estimated age-standardized 5-year, 10-year, and 20-year RS rates was 72%, 48%, and 31%, respectively. The SMR in the overall cohort was 4.6 (95% confidence interval, 4.22-5.0) or 21.0 (95% confidence interval, 16.6-27.2) in young adult patients and 3.0 (95% confidence interval, 2.6-3.4) in elderly patients. CONCLUSIONS: The elderly had a more aggressive form of this disease; and, other than the incidence, sex did not influence outcome in this disease. The study of chordomas presents a good case for the contribution that the SMR can have on measuring the impact of a disease on a population of patients. Although the younger population has better survival rates, the impact (SMR) in the younger age groups is much higher than in older populations.

show abstract

“…Foton-proton veya sadece proton protokolleriyle (79 CGE'ye kadar dozlarla) lokal kontrol oranlarını %85-100 arasında, sınırlı oranda ciddi yan etki ile bildiren çalışmalar vardır. [48][49][50] Karbon iyonları veya diğer yüklü partiküllerle radyoterapi, diğer cazip radyasyon modaliteleridir. Bu modaliteler de protonun fiziksel özellikleri ile, daha yüksek radyobiyolojik aktiviteyi birleştirir.…”

Section: Genel Bilgilerunclassified

Sık görülen primer malign kemik tümörlerinde radyoterapinin yeri ve tedaviye genel yaklaşım

Karakaya¹

2014

TOTBID

View full text Add to dashboard Cite

show abstract

Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut experience

Cited by 186 publications

References 31 publications

Radiotherapy Treatment of Early-Stage Prostate Cancer with IMRT and Protons: A Treatment Planning Comparison

Radiotherapy Treatment of Early-Stage Prostate Cancer with IMRT and Protons: A Treatment Planning Comparison

Incidence and relative survival of chordomas

Sık görülen primer malign kemik tümörlerinde radyoterapinin yeri ve tedaviye genel yaklaşım

Contact Info

Product

Resources

About